Pub Date : 2017-12-12DOI: 10.15406/ICPJL.2017.05.00138
N. Burela, N. Patni, Anjali Sharma
Primary malignant melanoma of genitourinary tract is rare and accounts for only 0.2% of all melanomas. Urethra is the most common site of origin, although primary malignant melanoma of urinary bladder is extremely rare.1 Only 24cases of primary malignant melanoma of urinary bladder are reported to date.2 Malignant melanomas of bladder are usually metastatic lesions, which originate from distant primary site rather than being a primary lesion.3 We report a case of primary malignant melanoma of urinary bladder.
{"title":"Primary malignant melanoma of urinary bladder","authors":"N. Burela, N. Patni, Anjali Sharma","doi":"10.15406/ICPJL.2017.05.00138","DOIUrl":"https://doi.org/10.15406/ICPJL.2017.05.00138","url":null,"abstract":"Primary malignant melanoma of genitourinary tract is rare and accounts for only 0.2% of all melanomas. Urethra is the most common site of origin, although primary malignant melanoma of urinary bladder is extremely rare.1 Only 24cases of primary malignant melanoma of urinary bladder are reported to date.2 Malignant melanomas of bladder are usually metastatic lesions, which originate from distant primary site rather than being a primary lesion.3 We report a case of primary malignant melanoma of urinary bladder.","PeriodicalId":92215,"journal":{"name":"International clinical pathology journal","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2017-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44484107","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-12-06DOI: 10.15406/ICPJL.2017.05.00137
K. Akhtar, M. Talha, R. Sherwani, S. Siddiqui
Breast cancer accounts for approximately one-quarter of all cancers in females worldwide and 27% of all cancers in developed countries with a western lifestyle [1]. It’s by far, the most frequent cancer among women, with an estimated 1.67 million new cases of breast cancer diagnosed in 2012 [2]. In India, about 145,000 new cases were diagnosed in 2012 and 70,000 deaths were attributed to it. The WHO Working Group has agreed on a more clinical follow-ups and a need of a genetic data for a better understanding of the natural history of these lesions [3]. Neurofibromatosis 1 is one of the most common genetic diseases in humans, presenting with multiple neurofibromas and an increased risk of various benign and malignant tumors, including breast cancer [4]. Neurofibromatosis type I (NF-1) is a complex multisystem autosomal dominant human disorder caused by the mutation of a gene on chromosome 17 which is responsible for production of a protein called neurofibromin. First report of an association between NF1 and breast cancer was published in 1972 [5] and subsequently several clinical cases of NF1 patients with breast cancer have been reported in the literature. Neurofibromatosis type II is a genetic condition which may be inherited or arise spontaneously. It’s caused by mutations in chromosome 22, also called as Merlin gene. The main manifestation of the condition is the development of symmetric, benign brain tumors in the region of the cranial nerve VIII. Schroeder et al. [5] first demonstrated an association between NF-2 and breast cancer [5]. Although only a minority of patients with NF1 develops malignancy as a complication of their disorder, cancer remains an important cause of morbidity and mortality in the disorder [4]. Moreover, oncologists may encounter patients with NF1 in the course of treatment for cancer, and need to be familiar with the diagnosis of the disorder and its clinical features.
{"title":"Infiltrating Ductal Carcinoma of Breast with Coexistent Neurofibroma-A Rare Association","authors":"K. Akhtar, M. Talha, R. Sherwani, S. Siddiqui","doi":"10.15406/ICPJL.2017.05.00137","DOIUrl":"https://doi.org/10.15406/ICPJL.2017.05.00137","url":null,"abstract":"Breast cancer accounts for approximately one-quarter of all cancers in females worldwide and 27% of all cancers in developed countries with a western lifestyle [1]. It’s by far, the most frequent cancer among women, with an estimated 1.67 million new cases of breast cancer diagnosed in 2012 [2]. In India, about 145,000 new cases were diagnosed in 2012 and 70,000 deaths were attributed to it. The WHO Working Group has agreed on a more clinical follow-ups and a need of a genetic data for a better understanding of the natural history of these lesions [3]. Neurofibromatosis 1 is one of the most common genetic diseases in humans, presenting with multiple neurofibromas and an increased risk of various benign and malignant tumors, including breast cancer [4]. Neurofibromatosis type I (NF-1) is a complex multisystem autosomal dominant human disorder caused by the mutation of a gene on chromosome 17 which is responsible for production of a protein called neurofibromin. First report of an association between NF1 and breast cancer was published in 1972 [5] and subsequently several clinical cases of NF1 patients with breast cancer have been reported in the literature. Neurofibromatosis type II is a genetic condition which may be inherited or arise spontaneously. It’s caused by mutations in chromosome 22, also called as Merlin gene. The main manifestation of the condition is the development of symmetric, benign brain tumors in the region of the cranial nerve VIII. Schroeder et al. [5] first demonstrated an association between NF-2 and breast cancer [5]. Although only a minority of patients with NF1 develops malignancy as a complication of their disorder, cancer remains an important cause of morbidity and mortality in the disorder [4]. Moreover, oncologists may encounter patients with NF1 in the course of treatment for cancer, and need to be familiar with the diagnosis of the disorder and its clinical features.","PeriodicalId":92215,"journal":{"name":"International clinical pathology journal","volume":"5 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2017-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42455520","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-12-04DOI: 10.15406/icpjl.2017.05.00136
G. Hachem
Submit Manuscript | http://medcraveonline.com 60% of newly diagnosed malignant tumors and 70% of cancer deaths occur in people aged 65 years or older [3]. In the literature, many cancers are linked to aging; these include breast, colorectal, prostate, pancreatic, lung and bladder carcinomas. Consequently, Medicine created the sub-specialty of Geriatric Oncology. This branch is mainly concerned by the diagnosis and treatment of cancers in the elderly, targeting the population aged 65 and older, while incorporating their special needs into the anti-neoplastic treatment. So, the age was transformed from an absolute chronological number to an association and accumulation of multiple comorbidities.
{"title":"Geriatric oncology: where age is not measured by years","authors":"G. Hachem","doi":"10.15406/icpjl.2017.05.00136","DOIUrl":"https://doi.org/10.15406/icpjl.2017.05.00136","url":null,"abstract":"Submit Manuscript | http://medcraveonline.com 60% of newly diagnosed malignant tumors and 70% of cancer deaths occur in people aged 65 years or older [3]. In the literature, many cancers are linked to aging; these include breast, colorectal, prostate, pancreatic, lung and bladder carcinomas. Consequently, Medicine created the sub-specialty of Geriatric Oncology. This branch is mainly concerned by the diagnosis and treatment of cancers in the elderly, targeting the population aged 65 and older, while incorporating their special needs into the anti-neoplastic treatment. So, the age was transformed from an absolute chronological number to an association and accumulation of multiple comorbidities.","PeriodicalId":92215,"journal":{"name":"International clinical pathology journal","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2017-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46916307","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-12-01DOI: 10.15406/ICPJL.2017.05.00134
Sirigireddy Sivajothi, B. Sudhakarareddy
Trypanosomosis is a haemoprotozoan disease of domestic and wild animals, spread by tabanid flies bites. The disease generally causes fever, anemia, myocarditis, corneal opacity and it is a fatal disease in canines [1]. Now a day’s many numbers of trypanosomacidal drugs are available including suramin, quinapyramine and diminazene. But, a single dose of the drug is not effective for horses, mules and dogs since diminazene aceturate neither crosses the blood-brain barrier nor insufficient doses were unable to control the T. evansi infection [2,3]. Present communication; put a record on the therapeutic efficacy of two doses of diminazene aceturate injections to treat dogs with T. evansi infection.
{"title":"Therapeutic management of anemia due to trypanosomosis in dogs","authors":"Sirigireddy Sivajothi, B. Sudhakarareddy","doi":"10.15406/ICPJL.2017.05.00134","DOIUrl":"https://doi.org/10.15406/ICPJL.2017.05.00134","url":null,"abstract":"Trypanosomosis is a haemoprotozoan disease of domestic and wild animals, spread by tabanid flies bites. The disease generally causes fever, anemia, myocarditis, corneal opacity and it is a fatal disease in canines [1]. Now a day’s many numbers of trypanosomacidal drugs are available including suramin, quinapyramine and diminazene. But, a single dose of the drug is not effective for horses, mules and dogs since diminazene aceturate neither crosses the blood-brain barrier nor insufficient doses were unable to control the T. evansi infection [2,3]. Present communication; put a record on the therapeutic efficacy of two doses of diminazene aceturate injections to treat dogs with T. evansi infection.","PeriodicalId":92215,"journal":{"name":"International clinical pathology journal","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2017-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47128497","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-11-28DOI: 10.15406/icpjl.2017.05.00133
Větvička, J. Větvičková
Submit Manuscript | http://medcraveonline.com III clinical trial evaluating the combination therapy of Imprime PGGTM and ErbituxTM in colorectal cancer patients. This study is currently enrolling up to 795 patients and will be conducted at 50 locations worldwide, including the U.S, France and Germany. Results achieved so far are highly promising showing the response rate for patients receiving glucan nearly doubled and median progression-free survival time increased 41%. In addition, Biothera announced that Imprime PGGTM had achieved significant results in meeting endpoint results in the Phase IIb NSCLC clinical trial. Patients in this trial had an objective response rate more than double compared to the control group. In the biomarkerpositive group, the results were even better. In case of chronic lymphocytic leukemia, a high number of patients with a complete response after Imprime and antibody combination is extremely impressive. It is even more impressive when we remember that today most cancer drugs have a response rate well below 40%.
{"title":"Glucan in clinical trials","authors":"Větvička, J. Větvičková","doi":"10.15406/icpjl.2017.05.00133","DOIUrl":"https://doi.org/10.15406/icpjl.2017.05.00133","url":null,"abstract":"Submit Manuscript | http://medcraveonline.com III clinical trial evaluating the combination therapy of Imprime PGGTM and ErbituxTM in colorectal cancer patients. This study is currently enrolling up to 795 patients and will be conducted at 50 locations worldwide, including the U.S, France and Germany. Results achieved so far are highly promising showing the response rate for patients receiving glucan nearly doubled and median progression-free survival time increased 41%. In addition, Biothera announced that Imprime PGGTM had achieved significant results in meeting endpoint results in the Phase IIb NSCLC clinical trial. Patients in this trial had an objective response rate more than double compared to the control group. In the biomarkerpositive group, the results were even better. In case of chronic lymphocytic leukemia, a high number of patients with a complete response after Imprime and antibody combination is extremely impressive. It is even more impressive when we remember that today most cancer drugs have a response rate well below 40%.","PeriodicalId":92215,"journal":{"name":"International clinical pathology journal","volume":"5 1","pages":"1-2"},"PeriodicalIF":0.0,"publicationDate":"2017-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41426459","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-11-17DOI: 10.15406/icpjl.2017.05.00132
E. Pardina, J. Carmona, J. Rossell, D. Ricart-Jané, Juan A Baena Fustegueras, J. Peinado-Onsurbe
The existing literature regarding the effect of stress on lipid metabolism [3,4] is sparse and, in the case of LPL, contradictory [5-7]. It has been described in rats, in vivo and in vitro that adrenaline causes a decrease in the LPL activity in the vascular bed of adipocytes, but expression of the gene encoding the enzyme was not affected [8], in parallel with an increase in plasma LPL activity as well as the appearance of LPL activity in the liver [9,10], but there is still controversy about the regulatory mechanism. To further the knowledge of LPL in vivo regulation by adrenaline, a model of restraint stress in rats was used and applied either as chronic and acute conditions [11]. Both chronic and acute stresses were reported to produce significant alterations in lipid and lipoprotein metabolism [11], and these changes were accompanied by a decrease in LPL activity in white adipose tissue and an increase in plasma [8]. The possible role of blood flow in the regulation of LPL by catecholamines has also been studied. Because of its intravascular location, it is possible that LPL is sensitive to variations in the flow of blood through the capillaries. Thus, an increased flow could lead to an increase in the release of LPL from its anchor, which would lead to a decline in activity in the tissue without altering its synthesis. This would provide a mechanism for short-term regulation if the LPL (much faster than the regulation of enzyme synthesis), which has not been studied yet. It has been reported that acute immobilization stress increased blood flow in white adipose tissue (which reduces LPL activity) but not in muscle (in which LPL was unchanged) [12]. It has also been reported that LPL shows a circadian rhythm in adult rats [13] that can be modified by soft stress [14]. However, there are very few data linking stress caused by with lipolytic activity. In experimental animals, HL activity and mRNA were shown to decrease in the liver after hepatectomy, whereas activity was not detected in the plasma. However, adrenal HL activity did not vary post-surgery [15]. This is very interesting because the steroidogenic organs, such as the adrenal gland, cannot synthesize the enzyme, which originates in the liver; however, given the need to capture cholesterol for the synthesis of catecholamines and glucocorticoids, such as in a stressful situation, steroidogenic organs retain high levels of HL. It has also been observed that surgical stress leads to the recovery of the LPL activity and mRNA in the liver, and there are also changes in the expression of LPL and other proteins, such as albumin, actin, etc, in peripheral tissues [16].
{"title":"Lipases and the stress of obesity","authors":"E. Pardina, J. Carmona, J. Rossell, D. Ricart-Jané, Juan A Baena Fustegueras, J. Peinado-Onsurbe","doi":"10.15406/icpjl.2017.05.00132","DOIUrl":"https://doi.org/10.15406/icpjl.2017.05.00132","url":null,"abstract":"The existing literature regarding the effect of stress on lipid metabolism [3,4] is sparse and, in the case of LPL, contradictory [5-7]. It has been described in rats, in vivo and in vitro that adrenaline causes a decrease in the LPL activity in the vascular bed of adipocytes, but expression of the gene encoding the enzyme was not affected [8], in parallel with an increase in plasma LPL activity as well as the appearance of LPL activity in the liver [9,10], but there is still controversy about the regulatory mechanism. To further the knowledge of LPL in vivo regulation by adrenaline, a model of restraint stress in rats was used and applied either as chronic and acute conditions [11]. Both chronic and acute stresses were reported to produce significant alterations in lipid and lipoprotein metabolism [11], and these changes were accompanied by a decrease in LPL activity in white adipose tissue and an increase in plasma [8]. The possible role of blood flow in the regulation of LPL by catecholamines has also been studied. Because of its intravascular location, it is possible that LPL is sensitive to variations in the flow of blood through the capillaries. Thus, an increased flow could lead to an increase in the release of LPL from its anchor, which would lead to a decline in activity in the tissue without altering its synthesis. This would provide a mechanism for short-term regulation if the LPL (much faster than the regulation of enzyme synthesis), which has not been studied yet. It has been reported that acute immobilization stress increased blood flow in white adipose tissue (which reduces LPL activity) but not in muscle (in which LPL was unchanged) [12]. It has also been reported that LPL shows a circadian rhythm in adult rats [13] that can be modified by soft stress [14]. However, there are very few data linking stress caused by with lipolytic activity. In experimental animals, HL activity and mRNA were shown to decrease in the liver after hepatectomy, whereas activity was not detected in the plasma. However, adrenal HL activity did not vary post-surgery [15]. This is very interesting because the steroidogenic organs, such as the adrenal gland, cannot synthesize the enzyme, which originates in the liver; however, given the need to capture cholesterol for the synthesis of catecholamines and glucocorticoids, such as in a stressful situation, steroidogenic organs retain high levels of HL. It has also been observed that surgical stress leads to the recovery of the LPL activity and mRNA in the liver, and there are also changes in the expression of LPL and other proteins, such as albumin, actin, etc, in peripheral tissues [16].","PeriodicalId":92215,"journal":{"name":"International clinical pathology journal","volume":" ","pages":"1-2"},"PeriodicalIF":0.0,"publicationDate":"2017-11-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49323568","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-11-16DOI: 10.15406/ICPJL.2017.5.00131
Simran Khanvekar, hya Tamgadge, A. Tamgadge
Tobacco, a product prepared by curing of the leaves of the tobacco plant, is a killer. It is the only legally available and commonly used substance that will kill one third to half of the people who use it.1 Tobacco is the major cause of preventable mortality and morbidity all over the world. The tobacco epidemic is one of the major public health threats with one million deaths attributed to tobacco each year in India. High prevalence of overall tobacco use and rise in its consumption amongst women and youth is a cause of concern. Besides health, tobacco also has huge impacts on the economy and environment.1,2 This damage from tobacco is attributed to the fact that most of the tobacco users are unaware of the dangers related to the habit.3 India is the second largest consumer of tobacco products (after China) in the world and the second largest producer of tobacco (after China). India is at the second stage of epidemic, where the percentages of smokers as well as deaths due to smoking are on the rise. The deaths caused by tobacco are more than those caused by Malaria, TB, and HIV/ AIDS combined. In India, smokeless from is more prevalent than the smoking form with 75% being daily users.2 The oral cavity is the first area of the body affected by tobacco products. Tobacco use impacts many oral conditions, including dental caries, periodontal diseases, oral cancers, impaired wound healing, reduced ability to smell and taste, staining of the teeth, leukoplakia, oral precancerous lesions, halitosis and implant failure.4
{"title":"Tobacco cessation-scissor the consumption-a review","authors":"Simran Khanvekar, hya Tamgadge, A. Tamgadge","doi":"10.15406/ICPJL.2017.5.00131","DOIUrl":"https://doi.org/10.15406/ICPJL.2017.5.00131","url":null,"abstract":"Tobacco, a product prepared by curing of the leaves of the tobacco plant, is a killer. It is the only legally available and commonly used substance that will kill one third to half of the people who use it.1 Tobacco is the major cause of preventable mortality and morbidity all over the world. The tobacco epidemic is one of the major public health threats with one million deaths attributed to tobacco each year in India. High prevalence of overall tobacco use and rise in its consumption amongst women and youth is a cause of concern. Besides health, tobacco also has huge impacts on the economy and environment.1,2 This damage from tobacco is attributed to the fact that most of the tobacco users are unaware of the dangers related to the habit.3 India is the second largest consumer of tobacco products (after China) in the world and the second largest producer of tobacco (after China). India is at the second stage of epidemic, where the percentages of smokers as well as deaths due to smoking are on the rise. The deaths caused by tobacco are more than those caused by Malaria, TB, and HIV/ AIDS combined. In India, smokeless from is more prevalent than the smoking form with 75% being daily users.2 The oral cavity is the first area of the body affected by tobacco products. Tobacco use impacts many oral conditions, including dental caries, periodontal diseases, oral cancers, impaired wound healing, reduced ability to smell and taste, staining of the teeth, leukoplakia, oral precancerous lesions, halitosis and implant failure.4","PeriodicalId":92215,"journal":{"name":"International clinical pathology journal","volume":"5 1","pages":"1-6"},"PeriodicalIF":0.0,"publicationDate":"2017-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42855133","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-11-10DOI: 10.15406/ICPJL.2017.05.00130
L. Bernstein
{"title":"Laboratory role in measuring transthyretin and homocysteine","authors":"L. Bernstein","doi":"10.15406/ICPJL.2017.05.00130","DOIUrl":"https://doi.org/10.15406/ICPJL.2017.05.00130","url":null,"abstract":"","PeriodicalId":92215,"journal":{"name":"International clinical pathology journal","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2017-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43430912","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-11-09DOI: 10.15406/ICPJL.2017.05.00129
A. Attar, Seham A Al Azreg, Oe Abdouslam
{"title":"Pigmented villonodular synovitis (PVNS) in human and animals: a mini review article and conclusive view","authors":"A. Attar, Seham A Al Azreg, Oe Abdouslam","doi":"10.15406/ICPJL.2017.05.00129","DOIUrl":"https://doi.org/10.15406/ICPJL.2017.05.00129","url":null,"abstract":"","PeriodicalId":92215,"journal":{"name":"International clinical pathology journal","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2017-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43660115","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：